Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mannan-conjugated birch pollen allergoid in allergic rhinitis/rhinoconjunctivitis
2023-508013-16-00Phase 3Completed
- Sponsor
- CCDRD
- Start
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) and allergic conjunctivitis (AC) comparing T502 mannan-conjugated birch pollen allergoid with Placebo (2 arms). Primary endpoint: Combined Symptom and Medication Score (CSMS) over peak birch pollen season 2024. Started Feb 2024; status: completed.
02
Drugs
mannan-conjugated betula pendula pollen allergoid vaccine
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2023-508013-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508013-16-00.